Rituxan associated with PML, warns US FDA

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2007年 / 1133卷 / 1期

关键词：

Health Care; Systemic Lupus Erythematosus; Viral Infection; Effective Treatment; Care Provider;

D O I：

10.2165/00128415-200711330-00006

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 50 条

[41] FDA warns compounders, veterinarians
不详
[J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2004, 224 (08): : 1226 - 1226
[42] FDA warns on imported drugs
不详
[J]. CHEMICAL & ENGINEERING NEWS, 2002, 80 (50) : 27 - 27
[43] FDA warns of oximeter flaws
Brainard, Jeffrey
[J]. SCIENCE, 2021, 371 (6532) : 869 - 869
[44] FDA warns of labeling violations
Nachay, Karen
[J]. FOOD TECHNOLOGY, 2010, 64 (04) : 12 - 13
[45] US FDA issues PML warning after Tecfidera-related death
[J]. Reactions Weekly, 2014, 1530 (1) : 5 - 5
[46] Roche warns about Rituxan-related intestinal obstruction/perforations
[J]. Reactions Weekly, 2006, 1128 (1) : 3 - 3
[47] US FDA advises of risk factor for PML, gives go ahead for test
[J]. Reactions Weekly, 2012, 1386 (1) : 2 - 2
[48] FDA warns of seizure risk with dalfampridine
[J]. Reactions Weekly, 2012, 1412 (1) : 2 - 2
[49] FDA warns about heartburn drug
Josefson, D
[J]. BRITISH MEDICAL JOURNAL, 1998, 317 (7151): : 101 - 101
[50] FDA warns Pfizer on sertraline marketing
Barnett, AA
[J]. LANCET, 1996, 348 (9025): : 469 - 469

← 1 2 3 4 5 →